Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

NCT01712919 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

RADIATION: Intensity-modulated radiotherapy
DRUG: Concurrent chemotherapy with paclitaxel and nedaplatin
BIOLOGICAL: Cetuximab

Sponsor

Jiangsu Cancer Institute & Hospital